Search: onr:"swepub:oai:prod.swepub.kib.ki.se:124946648" >
Relations of serum ...
Relations of serum COMP to cardiovascular risk factors and endothelial function in patients with rheumatoid arthritis treated with methotrexate and TNF-α inhibitors
-
Hjeltnes, G (author)
-
Hollan, I (author)
-
Forre, O (author)
-
show more...
-
Wiik, A (author)
-
Lyberg, T (author)
-
Mikkelsen, K (author)
-
- Agewall, S (author)
- Karolinska Institutet
-
show less...
-
(creator_code:org_t)
- 2012-06-01
- 2012
- English.
-
In: The Journal of rheumatology. - : The Journal of Rheumatology. - 0315-162X .- 1499-2752. ; 39:7, s. 1341-1347
- Related links:
-
http://kipublication...
-
show more...
-
https://doi.org/10.3...
-
show less...
Abstract
Subject headings
Close
- To examine whether serum level of cartilage oligomeric matrix protein (S-COMP) is related to methotrexate (MTX) or to MTX and tumor necrosis factor-α (TNF-α) combination treatment for rheumatoid arthritis (RA); and to investigate whether S-COMP is related to cardiovascular risk factors including endothelial dysfunction and level of anticitrullinated protein antibodies (ACPA) in patients with RA.Methods.Clinical and laboratory measures, including S-COMP and reactive hyperemic index (RHI), were examined in 55 consecutive patients with RA starting with either MTX (n = 34) or MTX and anti-TNF-α treatment (n = 21) at baseline, and after 6 weeks and 6 months.Results.S-COMP was similar in the 2 treatment regimens during followup. We found a positive relationship between S-COMP at baseline and the use of disease-modifying antirheumatic drugs the last year preceding the study (p = 0.001), and a negative relation to current use of systemic glucocorticosteroids (p = 0.044). The nonsignificant change in S-COMP between baseline and the 6-month followup was positively and independently related to change in ACPA level (p = 0.009). There was no significant association between RHI and level of S-COMP at baseline.Conclusion.The cartilage turnover marker S-COMP did not change significantly after 6 months’ treatment with MTX with or without a TNF-α inhibitor in patients with RA. The positive association between S-COMP and ACPA suggests that these factors might interact, and could both be contributors to an unknown link between inflammation and cartilage destruction in patients with RA. S-COMP was not related to endothelial function in patients with RA, or to other cardiovascular risk factors studied. Clinical Trials registration numberNCT00902005.
Publication and Content Type
- ref (subject category)
- art (subject category)
Find in a library
To the university's database